BioXcel Therapeutics, Inc. (BTAIQ) vs Redhill Biopharma Ltd. (RDHL)
- BioXcel Therapeutics, Inc. BTAIQ 0.03 0.00%
- Redhill Biopharma Ltd. RDHL 0.48 −4.00%
BioXcel Therapeutics, Inc. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. is the larger, with a market value of $4.4M against $2.3M — 1.9× the size. BioXcel Therapeutics, Inc. grew revenue faster over the last twelve months: −14.5% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Redhill Biopharma Ltd. leads on 8 and BioXcel Therapeutics, Inc. on 7.
Valuation
| Metric | BTAIQ | RDHL | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 19.25 |
| P/S | 1.23 | 0.00 | 2.11 |
| P/B | n/m | n/m | 1.78 |
| Price to free cash flow | n/m | n/m | 16.14 |
| EV/EBITDA | n/m | n/m | 12.58 |
| EV/Sales | 228.32 | 6.43 | 2.73 |
| Earnings yield | (12,633.33%) | (127,222.23%) | (4.38%) |
| Free cash flow yield | (5,602.20%) | (246,986.61%) | 0.00% |
Profitability
| Metric | BTAIQ | RDHL | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.10% | 35.16% | 53.94% |
| Operating margin | (6,054.72%) | 0.00% | 0.00% |
| Net margin | (9,549.87%) | 25.20% | 0.00% |
| Free cash flow margin | (6,860.38%) | 0.00% | 0.00% |
| Return on equity | 63.52% | 0.00% | (0.40%) |
| Return on assets | (259.62%) | 0.00% | (3.32%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack